+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

AI in Clinical and Molecular Diagnostics Market

  • PDF Icon

    Report

  • 112 Pages
  • October 2024
  • Region: Global
  • BCC Research
  • ID: 6014280
The AI in Clinical and Molecular Diagnostics Market was valued at USD 2.6 billion in 2024, and is expected to reach USD 8.9 billion by 2029, rising at a CAGR of 27.60%. The market is driven by the rising demand for accurate and efficient diagnostic solutions. Advances in AI technologies such as machine learning and deep learning are enhancing the capabilities of traditional diagnostic methods in areas like imaging, genomics and laboratory testing. Factors promoting market expansion include a growing emphasis on personalized medicine, the need for earlier disease detection and the integration of AI into healthcare systems.

Major players in the market are investing in R&D, fostering strategic partnerships and expanding their product portfolios to leverage emerging opportunities. Countries in North America, Europe and Asia-Pacific are prioritizing digital health initiatives and innovative diagnostic solutions. The use of AI in clinical and molecular diagnostics will only grow, leading to breakthroughs that will improve patient outcomes and healthcare efficiency in the forecast period of 2024 to 2029.

Report Scope

This report on the global market for AI in clinical and molecular diagnostics entails a comprehensive analysis of the market size, growth trends and segmentation by technology and application. It examines drivers, challenges and opportunities influencing the adoption of AI technologies in clinical and molecular diagnostics, focusing on specific applications in imaging, genomics and laboratory diagnostics. The report provides perspectives on the competitive environment, featuring profiles of leading companies and their strategic initiatives, as well as regional analyses that address the specific market dynamics in North America, Europe, Asia-Pacific, and the Rest of the World (RoW), which in this report includes Latin America and the Middle East and Africa. It also identifies emerging trends, such as the integration of AI in personalized medicine and telehealth. This report is an essential reference for stakeholders, including healthcare providers, technology developers and policymakers, seeking to navigate and capitalize on the evolving AI landscape in diagnostics.

The report includes:

  • 27 data tables and 41 additional tables
  • An analysis of the current and future global markets for AI in clinical and molecular diagnostics
  • Analyses of global market trends, with market revenue data (sales figures) for 2021-2023, estimates for 2024, and projected CAGRs through 2029
  • Estimates of the market size and revenue forecasts for the global market for AI in clinical and molecular diagnostics, with market share analysis by type of services, devices, and region
  • Discussion of the rising prevalence of chronic diseases, and technological advances in biomarker discovery, disease progression prediction, and personalized treatment strategies
  • Discussions of the market dynamics, opportunities and challenges, as well as emerging technologies
  • Overview of the sustainability trends and ESG developments in the industry, with emphasis on the ESG practices of leading companies, their ESG scores, and consumer attitudes
  • Competitive intelligence, including companies' market shares, recent M&A activity and venture funding
  • Profiles of the leading companies, including: Siemens Healthineers AG, F. Hoffmann-La Roche Ltd., Koninklijke Philips N.V., Fujifilm Holdings Corp., and Merative

Table of Contents

Chapter 1 Executive Summary
  • Market Outlook
  • Scope of Report
  • Market Summary
Chapter 2 Market Overview
  • Overview
  • History of AI
  • Rise of Machine Learning
  • Machine Learning vs. Deep Learning vs. Neural Networks
  • Types of Machine Learning
  • Advantages and Disadvantages of ML Algorithms
  • AI in Healthcare
  • AI in Clinical Diagnostics
  • AI in Molecular Diagnostics
Chapter 3 Market Dynamics
  • Overview
  • Market Drivers
  • Investment in the AI Health Sector
  • Increasing Prevalence of Chronic and Infectious Diseases
  • Technological Advances
  • Demand for Personalized Medicine
  • Market Restraints
  • Practitioners Reluctant to Adopt AI-based Technologies
  • Data Security
  • Regulatory Challenges
  • Market Opportunities
  • Software with AI
  • Untapped Opportunities in Developing Markets
Chapter 4 Regulatory Structure
Chapter 5 Emerging Technologies and Developments
  • Latest Technologies/Developments
  • Machine Learning Algorithms
  • Deep Learning
  • Generative AI
  • Natural Language Processing (NLP)
  • Genomic AI
  • Cloud-Based Solutions
Chapter 6 Market Segmentation Analysis
  • Market Trends
  • Segmentation Breakdown
  • AI in Clinical and Molecular Diagnostics: Global Markets
  • Molecular Diagnostics
  • Clinical Diagnostics
  • Market Analysis by Component
  • Software
  • Services
  • Hardware
  • Geographic Breakdown
  • Market Analysis by Region
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
Chapter 7 Competitive Intelligence
Chapter 8 Sustainability in AI in Clinical and Molecular Diagnostics: An ESG Perspective
  • Environmental Sustainability
  • Positive Environmental Impacts
  • Negative Environmental Impacts
  • Social: Ensuring that AI Benefits All Society
  • Governance Impacts
Chapter 9 Appendix
  • Methodology
  • Sources
  • Abbreviations
  • Company Profiles
  • ATOMWISE INC.
  • F. HOFFMANN-LA ROCHE LTD.
  • FUJIFILM HOLDINGS CORP.
  • GE HEALTHCARE
  • ILLUMINA INC.
  • KONINKLIJKE PHILIPS N.V.
  • MEDTRONIC
  • MICROSOFT CORP.
  • SIEMENS HEALTHINEERS AG
  • THERMO FISHER SCIENTIFIC INC.
  • Vendors
  • BUTTERFLY NETWORK INC.
  • ENLITIC
  • INTEL CORP.
  • MERATIVE
  • NVIDIA CORP.
  • QURE.AI
  • SYNAPSICA HEALTHCARE PVT LTD.
List of Tables
Summary Table A: Global Market for AI in Clinical and Molecular Diagnostics, by Type, Through 2029
Summary Table B: Global Market for AI in Clinical and Molecular Diagnostics, by Region, Through 2029
Table 1: Regulations Pertaining to AI Medical Diagnostics
Table 2: Global Market for AI in Clinical and Molecular Diagnostics, Through 2029
Table 3: Global Market for AI in Clinical and Molecular Diagnostics, by Type, Through 2029
Table 4: Global Market for AI in Molecular Diagnostics, by Application, Through 2029
Table 5: Incidence of Cancer, by Region, 2022
Table 6: Number of DALYs for Neurological Disorders and Share of Global DALYs Projected for 2005 and 2030
Table 7: Global Market for AI in Molecular Diagnostics, by Product Type, Through 2029
Table 8: Global Market for AI in Clinical Diagnostics, by Test, Through 2029
Table 9: Global Market for AI in Clinical Diagnostics, by Product, Through 2029
Table 10: Global Market for AI in Clinical and Molecular Diagnostics, by Component, Through 2029
Table 11: Global Market for AI in Clinical and Molecular Diagnostics, by Region, Through 2029
Table 12: North American Market for AI in Clinical and Molecular Diagnostics, by Country, Through 2029
Table 13: European Market for AI in Clinical and Molecular Diagnostics, by Country, Through 2029
Table 14: Asia-Pacific Market for AI in Clinical and Molecular Diagnostics, by Country, Through 2029
Table 15: RoW Market for AI in Clinical and Molecular Diagnostics, by Sub-Region, Through 2029
Table 16: Recent Initiatives in the Market for AI in Clinical and Molecular Diagnostics, 2024
Table 17: Report Sources
Table 18: Abbreviations Used in this Report
Table 19: Atomwise Inc.: Company Snapshot
Table 20: Atomwise Inc.: Product Portfolio
Table 21: Atomwise Inc: News/Key Developments, 2022
Table 22: F. Hoffmann-La Roche Ltd.: Company Snapshot
Table 23: F. Hoffmann-La Roche Ltd.: Financial Performance, FY 2022 and 2023
Table 24: F. Hoffmann-La Roche Ltd.: Product Portfolio
Table 25: Fujifilm Holdings Corp.: Company Snapshot
Table 26: Fujifilm Holdings Corp.: Financial Performance, FY 2022 and 2023
Table 27: Fujifilm Holdings Corp.: Product Portfolio
Table 28: GE HealthCare: Company Snapshot
Table 29: GE HealthCare: Financial Performance, FY 2022 and 2023
Table 30: GE HealthCare: Product Portfolio
Table 31: Illumina: Company Snapshot
Table 32: Illumina: Financial Performance, FY 2022 and 2023
Table 33: Illumina: Product Portfolio
Table 34: Koninklijke Philips N.V.: Company Snapshot
Table 35: Koninklijke Philips N.V.: Financial Performance, FY 2022 and 2023
Table 36: Koninklijke Philips N.V.: Product Portfolio
Table 37: Medtronic: Company Snapshot
Table 38: Medtronic: Financial Performance, FY 2022 and 2023
Table 39: Medtronic: Product Portfolio
Table 40: Microsoft Corp.: Company Snapshot
Table 41: Microsoft Corp.: Financial Performance, FY 2022 and 2023
Table 42: Microsoft Corp.: Product Portfolio
Table 43: Microsoft Corp.: News/Key Developments, 2024
Table 44: Siemens Healthineers AG: Company Snapshot
Table 45: Siemens Healthineers AG: Financial Performance, FY 2022 and 2023
Table 46: Siemens Healthineers AG: Product Portfolio
Table 47: Thermo Fisher Scientific Inc.: Company Snapshot
Table 48: Thermo Fisher Scientific Inc.: Financial Performance, FY 2022 and 2023
Table 49: Thermo Fisher Scientific Inc.: Product Portfolio
Table 50: Butterfly Network Inc.: Company Snapshot
Table 51: Butterfly Network Inc.: Financial Performance, FY 2022 and 2023
Table 52: Butterfly Network Inc.: Product Portfolio
Table 53: Enlitic: Company Snapshot
Table 54: Enlitic: Product Portfolio
Table 55: Intel Corp.: Company Snapshot
Table 56: Intel Corp.: Financial Performance, FY 2022 and 2023
Table 57: Intel Corp.: Product Portfolio
Table 58: Merative: Company Snapshot
Table 59: Merative: Product Portfolio
Table 60: NVIDIA Corp.: Company Snapshot
Table 61: NVIDIA Corp.: Financial Performance, FY 2022 and 2023
Table 62: NVIDIA Corp.: Product Portfolio
Table 63: Qure.ai: Company Snapshot
Table 64: Qure.ai: Product Portfolio
Table 65: Synapsica Healthcare Pvt Ltd.: Company Snapshot
Table 66: Synapsica Healthcare Pvt Ltd.: Product Portfolio
List of Figures
Summary Figure A: Global Market for AI in Clinical and Molecular Diagnostics, by Type, 2021-2029
Summary Figure B: Global Market for AI in Clinical and Molecular Diagnostics, by Region, 2021-2029
Figure 1: Market Dynamics of AI in Clinical and Molecular Diagnostics
Figure 2: Global Market Shares of AI in Clinical and Molecular Diagnostics, by Type, 2023
Figure 3: Global Market Shares of AI in Molecular Diagnostics, by Application, 2023
Figure 4: Global Deaths from Cancer, 2015 and 2030
Figure 5: Global Market Shares of AI in Molecular Diagnostics, by Product Type, 2023
Figure 6: Global Market Shares of AI in Clinical Diagnostics, by Test, 2023
Figure 7: Global Market Shares of AI in Clinical Diagnostics, by Product, 2023
Figure 8: Global Market Shares of AI in Clinical and Molecular Diagnostics, by Component, 2023
Figure 9: Global Market Shares of AI in Clinical and Molecular Diagnostics, by Region, 2023
Figure 10: North American Market Shares of AI in Clinical and Molecular Diagnostics, by Country, 2023
Figure 11: European Market Shares of AI in Clinical and Molecular Diagnostics, by Country, 2023
Figure 12: Asia-Pacific Market Shares of AI in Clinical and Molecular Diagnostics, by Country, 2023
Figure 13: RoW Market Shares of AI in Clinical and Molecular Diagnostics, by Sub-Region, 2023
Figure 14: F. Hoffmann-La Roche Ltd.: Revenue Share, by Business Unit, FY 2023
Figure 15: F. Hoffmann-La Roche Ltd.: Revenue Share, by Country/Region, FY 2023
Figure 16: Fujifilm Holdings Corp.: Revenue Share, by Business Unit, FY 2023
Figure 17: Fujifilm Holdings Corp.: Revenue Share, by Country/Region, FY 2023
Figure 18: GE HealthCare: Revenue Share, by Business Unit, FY 2023
Figure 19: GE HealthCare: Revenue Share, by Country/Region, FY 2023
Figure 20: Illumina: Revenue Share, by Business Unit, FY 2023
Figure 21: Illumina: Revenue Share, by Country/Region, FY 2023
Figure 22: Koninklijke Philips N.V.: Revenue Share, by Business Unit, FY 2023
Figure 23: Koninklijke Philips N.V.: Revenue Share, by Country/Region, FY 2023
Figure 24: Medtronic: Revenue Share, by Business Unit, FY 2023
Figure 25: Medtronic: Revenue Share, by Country/Region, FY 2023
Figure 26: Microsoft Corp.: Revenue Share, by Business Unit, FY 2023
Figure 27: Microsoft Corp.: Revenue Share, by Country/Region, FY 2023
Figure 28: Siemens Healthineers AG: Revenue Share, by Business Unit, FY 2023
Figure 29: Siemens Healthineers AG: Revenue Share, by Country/Region, FY 2023
Figure 30: Thermo Fisher Scientific Inc.: Revenue Share, by Business Unit, FY 2023
Figure 31: Thermo Fisher Scientific Inc.: Revenue Share, by Country/Region, FY 2023
Figure 32: Butterfly Network Inc.: Revenue Share, by Business Unit, FY 2023
Figure 33: Butterfly Network Inc.: Revenue Share, by Country/Region, FY 2023
Figure 34: Intel Corp.: Revenue Share, by Business Unit, FY 2023
Figure 35: Intel Corp.: Revenue Share, by Country/Region, FY 2023
Figure 36: NVIDIA Corp.: Revenue Share, by Business Unit, FY 2023
Figure 37: NVIDIA Corp.: Revenue Share, by Country/Region, FY 2023

Companies Mentioned

  • Atomwise Inc.
  • Butterfly Network Inc.
  • F. Hoffmann-La Roche Ltd.
  • Enlitic
  • Fujifilm Holdings Corp.
  • Intel Corp.
  • GE Healthcare
  • Merative
  • Illumina Inc.
  • Nvidia Corp.
  • Koninklijke Philips N.V.
  • Qure.AI
  • Medtronic
  • Synapsica Healthcare Pvt. Ltd.
  • Microsoft Corp.
  • Siemens Healthineers AG
  • Thermo Fisher Scientific Inc.

Table Information